ClinicalTrialsFinder

Autoimmune Lymphoproliferative Syndrome Clinical Trials in Houston, Texas

1 recruitingHouston, Texas

Showing 1–1 of 1 trials

Recruiting
Phase 2

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Autoimmune Lymphoproliferative Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)15 enrolled3 locationsNCT06730126